As gliomas are liable to develop drug resistance to TMZ in clinic, we studied whether co‐delivery of a BRD4 inhibitor (OTX) could suppress the tumor cells and re‐sensitize cells to TMZ (Figure 1D). Here, BRD4 is linked to central nervous system cancer.